ArticleChinese journal of integrative medicine2026
Berberine Suppresses Inflammatory Response in Severe Pneumonia by Specifically Targeting Upregulation of SIRT1 to Activate Nrf2 Signaling Pathway.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the key role of berberine (BER) in severe pneumonia progression, and analyze its potential mechanisms.
methodsGenes associated with pneumonia and their expression profiles were analyzed in patients with severe pneumonia compared with healthy controls, thereby identifying core targets. In vitro, RLE-6TN cells were stimulated with Klebsiella pneumoniae (KP) and treated with BER to investigate cellular responses and sirtuin 1/nuclear factor erythroid 2-related factor 2 (SIRT1/Nrf2) pathway activation. Additionally, an in vivo study was conducted in KP-infected rats to evaluate lung tissue pathology and gene expression.
resultsIn vitro experiments demonstrated that KP treatment of RLE-6TN cells significantly elevated lactate dehydrogenase activity, reduced cell viability and proliferation, and increased apoptosis (P<0.01). The expression levels of inflammatory markers (Bax, SIRT1, and Nrf2) were upregulated, whereas those of Bcl-2, Kiel proliferation index-67 (Ki-67), and proliferating cell nuclear antigen (PCNA) were downregulated (P<0.01). BER treatment mitigated these changes (P<0.01); however, sh-SIRT1 reversed the effects of BER, and sulforaphane (SFN, Nrf2 activator) counteracted the influence of sh-SIRT1 (P<0.05 or P<0.01). In vivo studies demonstrated that BER improved survival rates in KP-infected rats, alleviated lung injury, reduced pathological changes in lung tissue, and restored SIRT1 and Nrf2 to baseline levels (P<0.01). These advantageous effects were negated by sh-SIRT1 and subsequently restored by SFN (P<0.05 or P<0.01).
conclusionBER promoted the viability and proliferation of KP-treated RLE-6TN cells, inhibited cell apoptosis and inflammatory responses, and alleviated severe pneumonia through the SIRT1/Nrf2 signaling pathway activation.
Indexed as
Identifiers
42747758What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.